Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study

Abstract

Background Since the discovery of direct-acting antivirals, treatment for hepatitis C virus (HCV) is increasingly accessible in low-resource settings, but quality of care in these settings is not known. We described progression through the cascade of care among individuals who screened positive for HCV antibodies during a mass screening campaign in Kirehe and Kayonza, two rural Rwandan districts, in September 2019. Methods This retrospective cohort study used routine clinical data to assess proportions of participants completing each stage of the cascade of care, including: (a) screening positive on rapid diagnostic test; (b) return of initial viral load results; (c) detectable viral load; (d) treatment assessment; (e) treatment initiation; (f) return of sustained virological response (SVR12) results; and (g) achieving SVR12. We proposed three indicators to assess timely care provision and used medians and interquartile ranges (IQR) to describe the time to complete the cascade of care. Results Overall, 666 participants screened HCV positive, among them, 452 (68.1%) were female and median age was 61 years (IQR: 47, 70). Viral load results were returned for 537 (80.6%) participants of whom 448 (83.4%) had detectable viral loads. Of these, 398 (88.8%) were assessed for treatment, 394 (99%) were initiated, but only 222 (56.3%) had results returned for SVR12. Among those with SVR12 results, 208 (93.7%) achieved SVR12. When assessing timely care provision, we found 65.9% (95% CI: 62.0, 69.7) of initial viral load results were returned ≤ 30 days of screening; 45% (95% CI: 40.1, 49.8) of people with detectable viral load completed treatment assessment ≤ 90 days of initial viral load results; and 12.5% (95% CI: 9.2, 16.3) of SVR12 results were returned ≤ 210 days of treatment initiation among those who initiated treatment. The overall median time from screening to SVR12 assessment was 437 days. Conclusion Despite high rates of SVR12 among those who completed all stages of the cascade of care, we identified gaps and delays in the treatment cascade. Improving communication between viral load testing hubs and health facilities could reduce the turn-around time for viral load testing, and actively monitor timeliness of care provision could improve quality of HCV care.

Stages of care for patients with chronic hepatitis C at a hospital in southern Brazil

“…In addition, HNSC patients may have even started treatment due to the lack of clinical conditions, such as neoplasms or serious comorbidities. Not having genotyping or HCV-PCR test within a year are also bureaucratic reasons that interfere with the delay in starting HCV therapy, which is unfortunate given the possibility of simplified protocols with pangenotypic regimens[ 15 , 16 ].…”

Hepatocellular Carcinoma in Africa: Challenges and Opportunities

“…In 2018, 71.1 million people were estimated as worldwide chronic carriers of HCV; approximately 18 millions of them were in Africa (13) and are at risk of HCC development (14). HCV prevalence in SSA and North Africa is estimated at 2.1-3.3% and 2.3-7.7%, respectively (15).…”

“…Given the magnitude of Egypt's HCV and HCC problems, the extensive HCV treatment program could significantly impact the country's HCC figures shortly (19). Similarly, the Rwandan viral hepatitis program began in 2011, and the national hepatitis elimination strategy declared an ambitious goal of treating 90% of people affected by 2024 (13).…”

The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017–2019 Mass Screening and Treatment Campaign

“…One study that assessed the cascade of care in two rural districts of Rwanda found that 83.4% of patients tested for HCV had detectable viral loads. Almost everyone considered for treatment initiated treatment, while 93.7% of patients achieved SVR12 [ 25 ]. Although this study provided information on patients’ journeys in HCV care, the findings cannot be generalized, since the study was conducted in only two of the poorest districts of Rwanda and used a small sample size.…”